Skip to content
OpenCapital
Get started

Prelude Therapeutics PRLD Q4 2024 Annual earnings

Reported March 10, 2025 · Before market open

Revenue$4.0MDiluted EPS-$0.38Beat by $0.11
EPS estimate-$0.49

Next report

Aug 13, 2026 (in a month)
Revenue estimate$4.8M
EPS estimate-$0.23

Versus estimates

Revenue

Q1 2026$4.6MIn lineQ4 2025$5.6MMiss by $14.9MQ3 2025$6.5MMiss by $14.0M
Q4 2024$4.0M

Diluted EPS

Q1 2026-$0.13Beat by $0.14Q4 2025-$0.20Beat by $0.13Q3 2025-$0.26Beat by $0.09Q2 2025-$0.41Beat by $0.04Q1 2025-$0.42Beat by $0.05
Q4 2024-$0.38Beat by $0.11

Ask the moment Prelude Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Prelude Therapeutics report Q4 2024 earnings?
Prelude Therapeutics (PRLD) reported Q4 2024 earnings on March 10, 2025 before market open.
What were Prelude Therapeutics's Q4 2024 revenue and EPS?
Prelude Therapeutics reported revenue of $4.0M and diluted EPS of $-0.38 for Q4 2024.
Did Prelude Therapeutics beat estimates in Q4 2024?
EPS beat the consensus estimate of $-0.49 by $0.11.
Where can I find Prelude Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-035921) directly on SEC EDGAR. The filing index links above go to sec.gov.